Xeljanz Development Plans Scaled Back By Pfizer

The firm will deprioritize development of the oral JAK inhibitor in Crohn’s disease, ankylosing spondylitis and potentially psoriasis, while focusing on expansion in psoriatic arthritis and ulcerative colitis.